Literature DB >> 26796134

Four cases of investigational therapy with interleukin-11 against acute myocardial infarction.

Masashi Nakagawa1, Yasuko Owada2, Yasukatsu Izumi3,4, Shinichi Nonin1, Kenichi Sugioka1, Daisaku Nakatani5, Shinichi Iwata1, Kazuki Mizutani1, Satoshi Nishimura1, Asahiro Ito1, Suwako Fujita1, Takashi Daimon6, Yoshiki Sawa7, Masanori Asakura8, Makiko Maeda2, Yasushi Fujio9, Minoru Yoshiyama1.   

Abstract

We describe four cases of the patients with ST-elevation myocardial infarction (STEMI) that were treated with interleukin-11 (IL-11), a cardioprotective cytokine. Recombinant human IL-11 (rhIL-11), was intravenously administered to two cases at low dose (6 µg/kg) and to two at high dose (25 µg/kg). The cytokine administration started just after the coronary occlusion was confirmed by coronary angiography (CAG), taking 3 h. Following CAG, percutaneous coronary intervention (PCI) was performed as a standard therapy. No serious adverse drug reactions were observed. All the cases left the hospital without the symptom of heart failure. We discuss the possibility of the clinical use of rhIL-11 as an adjunct therapy to PCI for the STEMI patients.

Entities:  

Keywords:  Cytokine therapy; Interleukin-11; Postconditioning; Reperfusion injury; Translational research

Mesh：

Substances：

Year:  2016        PMID： 26796134     DOI： 10.1007/s00380-015-0788-4

Source DB:  PubMed          Journal:  Heart Vessels        ISSN： 0910-8327            Impact factor:   2.037


  14 in total

1.  Pharmacokinetics of recombinant human interleukin-11 (rhIL-11) in healthy male subjects.

Authors:  K Aoyama; T Uchida; F Takanuki; T Usui; T Watanabe; S Higuchi; T Toyoki; H Mizoguchi
Journal:  Br J Clin Pharmacol       Date:  1997-06       Impact factor: 4.335

Review 2.  Glycoprotein 130 cytokine signal as a therapeutic target against cardiovascular diseases.

Authors:  Yasushi Fujio; Makiko Maeda; Tomomi Mohri; Masanori Obana; Tomohiko Iwakura; Akiko Hayama; Tomomi Yamashita; Hiroyuki Nakayama; Junichi Azuma
Journal:  J Pharmacol Sci       Date:  2011-11-05       Impact factor: 3.337

3.  Therapeutic administration of IL-11 exhibits the postconditioning effects against ischemia-reperfusion injury via STAT3 in the heart.

Authors:  Masanori Obana; Kaori Miyamoto; Shiho Murasawa; Tomohiko Iwakura; Akiko Hayama; Tomomi Yamashita; Momoko Shiragaki; Shohei Kumagai; Akimitsu Miyawaki; Kana Takewaki; Goro Matsumiya; Makiko Maeda; Minoru Yoshiyama; Hiroyuki Nakayama; Yasushi Fujio
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-06-15       Impact factor: 4.733

Review 4.  FDA licensure of NEUMEGA to prevent severe chemotherapy-induced thrombocytopenia.

Authors:  J A Kaye
Journal:  Stem Cells       Date:  1998       Impact factor: 6.277

5.  Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies).

Authors:  Antonio Abbate; Michael Christopher Kontos; Nayef Antar Abouzaki; Ryan David Melchior; Christopher Thomas; Benjamin Wallace Van Tassell; Claudia Oddi; Salvatore Carbone; Cory Ross Trankle; Charlotte Susan Roberts; George Herman Mueller; Michael Lucas Gambill; Sanah Christopher; Roshanak Markley; George Wayne Vetrovec; Charles Anthony Dinarello; Giuseppe Biondi-Zoccai
Journal:  Am J Cardiol       Date:  2014-11-13       Impact factor: 2.778

6.  Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice.

Authors:  Kerstin Boengler; Astrid Buechert; Yvonne Heinen; Christin Roeskes; Denise Hilfiker-Kleiner; Gerd Heusch; Rainer Schulz
Journal:  Circ Res       Date:  2007-10-25       Impact factor: 17.367

7.  Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials.

Authors:  Masafumi Kitakaze; Masanori Asakura; Jiyoong Kim; Yasunori Shintani; Hiroshi Asanuma; Toshimitsu Hamasaki; Osamu Seguchi; Masafumi Myoishi; Tetsuo Minamino; Takahiro Ohara; Yoshiyuki Nagai; Shinsuke Nanto; Kouki Watanabe; Shigeru Fukuzawa; Atsushi Hirayama; Natsuki Nakamura; Kazuo Kimura; Kenshi Fujii; Masaharu Ishihara; Yoshihiko Saito; Hitonobu Tomoike; Soichiro Kitamura
Journal:  Lancet       Date:  2007-10-27       Impact factor: 79.321

8.  Identification of cardiac myocytes as the target of interleukin 11, a cardioprotective cytokine.

Authors:  Ryusuke Kimura; Makiko Maeda; Atsushi Arita; Yuichi Oshima; Masanori Obana; Takashi Ito; Yasuhiro Yamamoto; Tomomi Mohri; Tadamitsu Kishimoto; Ichiro Kawase; Yasushi Fujio; Junichi Azuma
Journal:  Cytokine       Date:  2007-07-16       Impact factor: 3.861

9.  Therapeutic activation of signal transducer and activator of transcription 3 by interleukin-11 ameliorates cardiac fibrosis after myocardial infarction.

Authors:  Masanori Obana; Makiko Maeda; Koji Takeda; Akiko Hayama; Tomomi Mohri; Tomomi Yamashita; Yoshikazu Nakaoka; Issei Komuro; Kiyoshi Takeda; Goro Matsumiya; Junichi Azuma; Yasushi Fujio
Journal:  Circulation       Date:  2010-01-25       Impact factor: 29.690

10.  Long-term incidence and prognostic factors of the progression of new coronary lesions in Japanese coronary artery disease patients after percutaneous coronary intervention.

Authors:  Hidehiro Kaneko; Junji Yajima; Yuji Oikawa; Shingo Tanaka; Daisuke Fukamachi; Shinya Suzuki; Koichi Sagara; Takayuki Otsuka; Shunsuke Matsuno; Hiroto Kano; Tokuhisa Uejima; Akira Koike; Kazuyuki Nagashima; Hajime Kirigaya; Hitoshi Sawada; Tadanori Aizawa; Takeshi Yamashita
Journal:  Heart Vessels       Date:  2013-06-27       Impact factor: 2.037
View more
  5 in total

1.  IL-11 is a crucial determinant of cardiovascular fibrosis.

Authors:  Sebastian Schafer; Sivakumar Viswanathan; Anissa A Widjaja; Wei-Wen Lim; Aida Moreno-Moral; Daniel M DeLaughter; Benjamin Ng; Giannino Patone; Kingsley Chow; Ester Khin; Jessie Tan; Sonia P Chothani; Lei Ye; Owen J L Rackham; Nicole S J Ko; Norliza E Sahib; Chee Jian Pua; Nicole T G Zhen; Chen Xie; Mao Wang; Henrike Maatz; Shiqi Lim; Kathrin Saar; Susanne Blachut; Enrico Petretto; Sabine Schmidt; Tracy Putoczki; Nuno Guimarães-Camboa; Hiroko Wakimoto; Sebastiaan van Heesch; Kristmundur Sigmundsson; See L Lim; Jia L Soon; Victor T T Chao; Yeow L Chua; Teing E Tan; Sylvia M Evans; Yee J Loh; Muhammad H Jamal; Kim K Ong; Kim C Chua; Boon-Hean Ong; Mathew J Chakaramakkil; Jonathan G Seidman; Christine E Seidman; Norbert Hubner; Kenny Y K Sin; Stuart A Cook
Journal:  Nature       Date:  2017-11-13       Impact factor: 49.962

2.  Plasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk.

Authors:  Dorette Raaz-Schrauder; Michael G Schrauder; Christian Stumpf; Piotr Lewczuk; Tobias Kilian; Barbara Dietel; Christoph D Garlichs; Christian Schlundt; Stephan Achenbach; Lutz Klinghammer
Journal:  Heart Vessels       Date:  2017-05-31       Impact factor: 2.037

3.  The cardioprotective effect of interleukin-11 against ischemia-reperfusion injury in a heart donor model.

Authors:  Yusaku Tamura; Hiroki Kohno; Tomomi Mohri; Yasushi Fujio; Goro Matsumiya
Journal:  Ann Cardiothorac Surg       Date:  2018-01

Review 4.  Single-Cell RNA Sequencing of the Cardiovascular System: New Looks for Old Diseases.

Authors:  Farhan Chaudhry; Jenna Isherwood; Tejeshwar Bawa; Dhruvil Patel; Katherine Gurdziel; David E Lanfear; Douglas M Ruden; Phillip D Levy
Journal:  Front Cardiovasc Med       Date:  2019-12-10

5.  Interleukin-11 signaling promotes cellular reprogramming and limits fibrotic scarring during tissue regeneration.

Authors:  Srinivas Allanki; Boris Strilic; Lilly Scheinberger; Yeszamin L Onderwater; Alora Marks; Stefan Günther; Jens Preussner; Khrievono Kikhi; Mario Looso; Didier Y R Stainier; Sven Reischauer
Journal:  Sci Adv       Date:  2021-09-08       Impact factor: 14.136
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.